JP Morgan Healthcare Conference and Biotech Showcase 2026
Advancing biopharma assets in today’s market demands speed, precision and flexibility. At Syneos Health®, we bring together integrated clinical, medical and commercial expertise to support companies working to deliver life-changing therapies to patients.
Meet with Us
If you’ll be in San Francisco for JP Morgan or Biotech Showcase 2026, let’s connect. We’re eager to learn more about your goals and explore how our solutions might align with your strategic priorities. Our team is equipped to support:
- Clinical development acceleration through agile operating models and tech-enabled innovation
- Bespoke biopharma partnerships that preserve momentum and culture—without adding fixed infrastructure
- Data-driven portfolio strategy to help prioritize and position your pipeline for maximum ROI
- Real-world insights integration to inform smarter trial design and de-risk development
- Fit-for-purpose commercialization options that enable flexible launch planning and investor-aligned GTM strategies
Featured Sessions
PANEL | Dealmakers’ Intentions 2026
Monday, January 12 | 3:30pm PT
Katya Magonova, Managing Director, Commercial Advisory, Syneos Health
Related Content
INSIGHTS:
The FSP 360 Advantage: Agility That Outpaces Traditional Models
Mastering Multiple Product Launches: A Roadmap to Pharma Launch Excellence
Investing for Launch Success: What Matters Most and When
From PoC to Global: How Emerging Biotechs Can De-Risk Phase II/III
Going Global: A “Three-V” Framework for Biopharma Market Expansion
Plan for US Policy Uncertainty to Increase Global Commercial Opportunity for Launch Assets
CAPABILITIES:
Oncology Expertise at All Levels
Neuroscience: Experience and Expertise to Accelerate Drug Development Success
CCO Pharma Commercialization Solutions - Maximize Launch Success
